Frequently Reported Adverse Events With Smoking Cessation Medications: Post Hoc Analysis of a Randomized Trial

Area of Science:

• Pharmacology
• Clinical Trials
• Public Health

Background:

• Smoking cessation pharmacotherapies are crucial for public health initiatives.
• Understanding adverse event (AE) profiles is vital for patient adherence and treatment success.
• Previous studies have suggested varying AE profiles among different smoking cessation aids.

Purpose of the Study:

• To compare the incidence, severity, and clinical course of frequently reported adverse events (AEs) after treatment with smoking cessation pharmacotherapies.
• To analyze AE data from a large-scale, multinational, randomized controlled trial (EAGLES).
• To provide comparative safety data for varenicline, bupropion, and nicotine patch treatments.

Main Methods:

• Post hoc analysis of treatment-emergent AEs from the phase 4, double-blind, randomized, placebo-controlled EAGLES trial (N=8144).
• Inclusion of smokers with and without psychiatric disorders.
• Comparison of varenicline, bupropion sustained-release, and nicotine patch treatments regarding AE incidence, time to onset, and duration.

Main Results:

• Nausea, insomnia, abnormal dreams, anxiety, irritability, dry mouth, fatigue, and application site pruritus differed significantly between active treatments and placebo.
• Specific risk differences were calculated for key AEs (e.g., nausea with varenicline vs. nicotine patch: 15.50%).
• Severe AEs and treatment discontinuation rates were low across all groups (<1.5% and <3%, respectively).

Conclusions:

• Active smoking cessation pharmacotherapies demonstrated well-tolerated and comparable AE profiles.
• The majority of reported AEs were not clinically significant and are manageable for patients.
• Prescribers can confidently use these treatments, reassuring patients about potential AE management.